Clinical Trials Logo

Alpha 1-Antitrypsin Deficiency clinical trials

View clinical trials related to Alpha 1-Antitrypsin Deficiency.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05899673 Enrolling by invitation - Clinical trials for Alpha1-Antitrypsin Deficiency

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Start date: August 8, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who are currently taking part in or have completed previous fazirsiran studies (AROAAT2001 [NCT03945292] or AROAAT2002 [NCT03946449]) can continue to receive fazirsiran in this study. Participants will receive fazirsiran every 3 months for almost 2 years and will then be followed for an additional 6 months. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

NCT ID: NCT02796937 Enrolling by invitation - Clinical trials for Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

SPARTA-OLE
Start date: July 2016
Phase: Phase 3
Study type: Interventional

This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60 mg/kg/week in subjects with alpha1-antitrypsin deficiency (AATD).

NCT ID: NCT00884455 Enrolling by invitation - Clinical trials for Alpha 1 Antitrypsin Deficiency

Alpha-1 Foundation DNA and Tissue Bank

Start date: December 2002
Phase:
Study type: Observational

This is a long-term follow-up banking protocol that collects medical information and tissue (blood, liver and lung) samples for future research; use of data and samples for research purposes is overseen by the Tissue Bank Advisory Committee; the purpose of the Bank is to further research on alpha-1 antitrypsin deficiency.